NIFTY 50

Biocon's partner to not initiate Itolizumab Ph 3 trials, co seeks to modify Ph 4 trials in India

Updated : December 03, 2020 02:55 PM IST

In October, Equillium had said that it had got USFDA clearance to begin a Phase 3 clinical trials.
Biocon's drug Itolizumab has emergency approval for COVID-19 treatment in India.

You May Also Like

Live TV

recommended for you